Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.

This study found that non-small-cell lung cancer patients experienced less adverse events with third-generation EGFR-TKIs compared to first and second generations, although fear of cancer progression, anxiety, and depression were still prevalent.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This study found that Brazilian patients with advanced NSCLC required significant survival gains to accept treatments causing severe tiredness or skin rash, with preferences varying among treatment options.

This study used a 3D bioprinted human lung cancer model in a mouse phantom to demonstrate a selective cytotoxic effect of X-rays on tumor cells, revealing differences from 2D cell models.

This review highlights that direct drug delivery to the lungs for treating lung cancer may offer more precise targeting while reducing side effects compared to traditional methods.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This review discusses the potential of natural products to induce ferroptosis as a promising therapeutic strategy for non-small cell lung cancer and reports no clinical results; the authors highlight the need for further comprehensive studies.

This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

In this study, aumolertinib improved general health status, functional status, and key symptoms for patients with advanced NSCLC, with an objective response rate of 65.2% and disease control rate of 91.3%, suggesting efficacy and quality of life benefits in first-line treatment.

In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.

This study found that, among patients with NSCLC after EGFR-TKI failure, pemetrexed is as effective as docetaxel but has fewer side effects, suggesting it may be a suitable salvage chemotherapy option.

This study found that anti-angiogenic drugs did not significantly affect COVID-19 severity, ICU admission, or mortality in patients with non-small cell lung cancer.

In this study, combining pemetrexed with cisplatin in non-small cell lung cancer patients improved immune function and had lower blood toxicity compared to cisplatin with gemcitabine, despite similar disease control rates and other side effects between the two treatment groups.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This study concluded that adding Kanglaite injection to gemcitabine and cisplatin chemotherapy for advanced non-small cell lung cancer improved response rates and reduced adverse side effects.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.

This study found that using a pH-sensitive layered double hydroxide nanocarrier to deliver etoposide significantly reduced liver toxicity and enhanced the drug’s effectiveness in targeting and suppressing non-small cell lung cancer.

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

This study demonstrates that a 3D-printed agarose microwell platform supports the growth of size-uniform, viable NSCLC cancer spheroids, and can effectively evaluate drug responses using limited tumor material from biopsies, particularly with EGFR tyrosine kinase inhibitors gefitinib and osimertinib.

This study observed that nuclear β-catenin expression in non-small-cell lung carcinomas correlates with increased proliferation and loss of key cell-cycle checkpoints, suggesting an oncogenic advantage.